Keyphrases
Quality of Life
100%
Health-related Quality of Life
100%
Real Patients
100%
Mental Health
100%
Melanoma
100%
Stage III-IV
100%
Adjuvant Immunotherapy
100%
Active Treatment
30%
Health Impact
20%
Comorbidity
20%
Employment Status
20%
Treatment Status
20%
Civil Status
20%
Nivolumab
20%
Denmark
10%
Cognitive Function
10%
Multivariable
10%
Patient-completed
10%
Patient Characteristics
10%
Validated Questionnaire
10%
Phase II Trial
10%
Sectional Analysis
10%
Adjuvant Therapy
10%
Metastatic Melanoma
10%
Treatment Quality
10%
Neoadjuvant Setting
10%
Immune Toxicity
10%
Immune Checkpoint Inhibitors
10%
Fear of Recurrence
10%
Decision Regret
10%
Ending Therapy
10%
Medicine and Dentistry
Quality of Life
100%
Mental Health
100%
Nodular Melanoma
100%
Immunotherapy
100%
Nivolumab
18%
Recurrent Disease
9%
Patient Characteristics
9%
Cross Sectional Study
9%
Adjuvant Therapy
9%
Metastatic Melanoma
9%
Cognition
9%
Immune Checkpoint Inhibitor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Melanoma
100%
Comorbidity
66%
Nivolumab
66%
Cross Sectional Study
33%
Recurrent Disease
33%
Metastatic Melanoma
33%
Immune Checkpoint Inhibitor
33%
Immunology and Microbiology
Mental Health
100%
Immunotherapy
100%
Comorbidity
66%
Nivolumab
66%
Cognition
33%
Psychology
Quality of Life
100%
Mental Health
100%
Comorbidity
18%
Cognitive Function
9%